1. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. (25th September 2019) Authors: Yoshioka, H; Shimokawa, M; Seto, T; Morita, S; Yatabe, Y; Okamoto, I; Tsurutani, J; Satouchi, M; Hirashima, T; Atagi, S; Shibata, K; Saito, H; Toyooka, S; Yamamoto, N; Nakagawa, K; Mitsudomi, T Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1978 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗